This provides evidence that, in the future,it will be important to consider the precise cellular and subcellularsolution environment if we are to successfully stabilize monomericTDP-43, in efforts to develop this as a viable therapeutic strategyto treat TDP-43 associated proteinopathies. The gene discussed is TARDBP; the disease is proteostasis deficiencies.